# Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

> **NCT00479674** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 41 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Abraxane
- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00479674
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2015-02-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00479674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00479674, "Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00479674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*